Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab utilization and impact in ulcerative colitis
NCT02092285Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- May 2014
- Primary completion
- May 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of golimumab in ulcerative colitis (UC), sponsored by Merck & Co.. Started May 2014; status: completed.
02
Drugs
golimumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02092285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02092285.